Deep mutational scanning of proteins in mammalian cells

S Maes, N Deploey, F Peelman, S Eyckerman - Cell Reports Methods, 2023 - cell.com
Protein mutagenesis is essential for unveiling the molecular mechanisms underlying protein
function in health, disease, and evolution. In the past decade, deep mutational scanning …

Molecular Mechanisms and Clinical Phenotypes of GJB2 Missense Variants

L Mao, Y Wang, L An, B Zeng, Y Wang, D Frishman… - Biology, 2023 - mdpi.com
Simple Summary Hearing loss is the most common sensory impairment in humans. Globally,
GJB2 is the most common responsible gene, with missense variants being the most frequent …

Saturation profiling of drug-resistant genetic variants using prime editing

Y Kim, HC Oh, S Lee, HH Kim - Nature Biotechnology, 2024 - nature.com
Methods to characterize the functional effects of genetic variants of uncertain significance
(VUSs) have been limited by incomplete coverage of the mutational space. In clinical …

Preclinical Anticipation of On-and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review

PJ Dziubańska-Kusibab, E Nevedomskaya… - International Journal of …, 2024 - mdpi.com
The advent of targeted therapies has led to tremendous improvements in treatment options
and their outcomes in the field of oncology. Yet, many cancers outsmart precision drugs by …

[HTML][HTML] The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review

A Belloni, A Pugnaloni, MR Rippo, S Di Valerio… - Critical Reviews in …, 2024 - Elsevier
Abstract Non-Small Cell Lung Cancer (NSCLC) represents∼ 85% of all lung cancers and∼
15–20% of them are characterized by mutations affecting the Epidermal Growth Factor …

Six first-line tyrosine kinase inhibitors reveal novel inhibition potential for the EGFR S768I mutation

Y Wang, Q Liu, C Chu, L Li, Z Wang, Q Liu, G Wu… - Toxicology and Applied …, 2023 - Elsevier
Lung cancer, the leading cause of cancer-related mortality, is the most commonly diagnosed
cancer. Tyrosine kinase inhibitors (TKIs) are considered a drug-targeted therapy for non …

A novel role for WZ3146 in the inhibition of cell proliferation via ERK and AKT pathway in the rare EGFR G719X mutant cells

L Li, C Liu, R Wang, X Yang, X Wei, C Chu, G Zhang… - Scientific Reports, 2024 - nature.com
Mutations in the epidermal growth factor receptor (EGFR) gene are common driver
oncogenes in non-small cell lung cancer (NSCLC). Studies have shown that afatinib is …

Saturation resistance profiling of EGFR variants against tyrosine kinase inhibitors using prime editing

Y Kim, HC Oh, S Lee, HH Kim - bioRxiv, 2023 - biorxiv.org
Variants of uncertain significance (VUS) hamper the clinical application of genetic
information. For example, in treating lung cancer with tyrosine kinase inhibitors (TKIs), many …

CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells

Z Wang, L Li, C Chu, X Wei, Q Liu… - International …, 2023 - spandidos-publications.com
Bladder cancer is one of the most common urological malignancies worldwide. The
molecular mechanism underlying its development is complex, but its carcinogenesis has …

Validation and benchmarking of targeted panel sequencing for cancer genomic profiling

D Wang, S Wang, Y Zhang, X Cheng… - American Journal of …, 2023 - academic.oup.com
Objectives To validate a large next-generation sequencing (NGS) panel for comprehensive
genomic profiling and improve patient access to more effective precision oncology treatment …